Network Meta-analysis on insulin compound preparation in treatment of type 2 diabetes
Objective To compare the efficacy and safety among insulin degludec and insulin aspart(IDegAsp),insulin degludec and liraglutide(IDegLira),and insulin glargine and lixisenatide(iGlarlixi)in treatment of type 2 diabetes by network Meta-analysis.Methods Domestic and foreign database were comprehensively searched to identify randomized controlled trials(RCTs)of effects of IDegAsp,IDegLira,and iGlarlixi from inception to July 18,2024.The outcomes were the achieving an HbA1c<7%,HbA1c,body weight,fasting plasma glucose,and incidence of hypoglycaemia.R software was used to conduct Bayesian network Meta-analysis and drawing the league map of pairwise comparison.The ranking probabilities of all treatments on efficacy and safety outcomes were displayed on their surface under the cumulative ranking(SUCRA)probabilities.Results A total of 25 RCTs were included in the analysis.IDegLira had the best effect on increasing the proportion of patients with HbA1c<7%,reducing glycated hemoglobin,reducing body weight,and lowering the incidence of hypoglycemia.IGlarlixi was superior to basal insulin in achieving an HbA1c<7%,decreasing HbA1c,and losing body weight.According to the ranking results,IDegLira might better in achieving an HbA1c<7%,decreasing HbA1c and fasting plasma glucose,losing body weight and reducing incidence of hypoglycaemia.Conclusion IDegLira has therapeutic advantages in improving HbA1c and reducing body weight,while also having safety advantages in reducing the risk of hypoglycemia.
insulin degludec and insulin aspartinsulin degludec and liraglutideinsulin glargine and lixisenatidetype 2 diabetesHbA1c<7%HbA1cbody weightfasting plasma glucoseincidence of hypoglycaemianetwork Meta-analysis
NETL
NSTL
万方数据
